键凯科技(688356) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached CNY 316.09 million, a year-on-year increase of 39.19%[5] - Net profit attributable to shareholders of the parent company was CNY 63.39 million, up 112.46% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 49.44 million, reflecting a growth of 153.79%[5] - Basic earnings per share increased to CNY 1.05, representing a 114.29% rise year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 1,419.87 million, a 3.85% increase from the beginning of the period[6] - Shareholders' equity attributable to the parent company grew to CNY 1,319.31 million, up 4.15% from the start of the period[6] - The weighted average return on net assets improved to 4.90%, an increase of 2.55 percentage points[5] Business Growth Drivers - The significant growth in revenue and profit was primarily driven by a notable increase in overseas business, particularly in new drug sales and medical device orders[7] - The company reported a substantial increase in orders from its largest overseas medical device client, contributing to steady revenue growth in this segment[7] Reporting Accuracy - There are no major uncertainties affecting the accuracy of the performance report, and the data is preliminary and subject to final audit[10]